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Summary Lumbar bone mineral density (BMD) determination by dual photon absorptiometry was used to
study the influence of adjuvant chemotherapy for premenopausal breast cancer on the risk of premature
osteoporosis. Six cycles of combination chemotherapy caused ovarian failure in 31 of 44 (71%) women,
amenorrhoea mostly already beginning during treatment. In contrast, only seven of 44 (16%) women, who
were pair-matched for age and year of breast cancer surgery and had not been treated with chemotherapy,
were post-menopausal at the time of measurement. The mean interval after breast surgery was 3.5 years. The
significantly decreased BMD in the treated group (1.17 compared to 1.29 g cm-2) could only be explained by
the high incidence of menopause in these women, which on average occurred 10 years prematurely. Extrapola-
tion of these findings suggests that adjuvant chemotherapy may precipitate osteoporotic fractures by some 10
years in a considerable proportion of women cured of premenopausal breast cancer.
Gradual loss of bone matrix and mineral is a consequence of
ageing leading to osteoporosis. In general, women start off
with less peak adult bone mass than men and consequently
develop more symptoms from osteoporosis. As a result a
considerable proportion of women suffer from spontaneous
fractures in later life (Gordan, 1978; Nordin, 1980; NIH
Consensus Statement, 1984). Various data suggest that in
osteoporosis there is a disproportionately greater loss of
trabecular bone from the axial skeleton compared to cortical
bone from appendicular sites (Riggs et al., 1981).
The average annual loss of bone mass measured by bone
mineral density (BMD) in women before menopause
amounts to 1-2%, but may rise to some 6-8% during the
first 2-5 years after menopause (Krolner & Pors Nielsen,
1982; Genant et al., 1982). This dramatic temporary increase
in the rate of bone loss around natural menopause or after
bilateral ovariectomy has been ascribed to a ceasing protec-
tion from bone loss by ovarian hormones (Riggs et al., 1981,
1982, 1986; Genant et al., 1982; Johnston et al., 1985; Richel-
son et al., 1984). Oestrogen replacement therapy effectively
prevents osteoporosis in post-menopausal women if started
within a few years after menopause (Riis, 1987; Lindsay et
al., 1976; Christiansen et al., 1980; Recker et al., 1977).
Adjuvant chemotherapy in premenopausal women treated
for breast cancer frequently leads to diminished ovarian func-
tion and premature menopause (Henderson, 1987). Since
early menopause is one of the strongest predictors of
osteoporosis (Richelson et al., 1984), we anticipated that the
widely used adjuvant chemotherapy regimen of cyclophos-
phamide, methotrexate and 5-fluorouracil (CMF), might
seriously precipitate osteoporosis.
To investigate this possibility we have compared the bone
mineral density of the lumbar spine between women who had
been treated with adjuvant CMF and women, matched for
age and time of premenopausal breast cancer surgery, who
received no such treatment.
Materials and methods
Eighty-eight caucasian female patients constituted 44 pairs of
cases and controls. Women regarded as cases had received six
cycles of CMF adjuvant chemotherapy (Bonadonna et al.,
1985) after primary treatment of premenopausal breast
cancer with axillary lymph node metastases (pT13, N1-2 MO).
Controls had not been given adjuvant chemotherapy as their
axillary nodes were histologically free of cancer. Cases and
controls were pair-matched for age (± 1 year) and the year of
primary treatment in the period 1981-1985. The age at the
time of measurement ranged from 35 to 50 years (median
43.0, mean 43.8) for cases, and from 34 to 52 years (median
45.1, mean 44.1) for controls. The interval between primary
surgery and the measurement of BMD was 17-78 months
(mean 40) for cases and 21-73 months (mean 44) for cont-
rols. All women were menstruating normally when first
treated for breast cancer and all were free of disease at the
time of the investigation. Only women who could recall the
year of their last menses and who had not undergone
hysterectomy were eligible. Women on oral contraceptives,
oestrogen replacement therapy, corticosteroids, vitamin D or
treatment for thyroid disorders were considered ineligible.
Patients were considered post-menopausal when they were
amenorrhoeic at the time of measurement, still were during
at least one year thereafter, and had serum FSH levels
>20 IU ml-' (2nd International Reference Preparation 78/
549). FSH was determined with a double antibody radioim-
muno assay kit from Diagnostic Products Corp. (Los
Angeles, CA, USA). Additional information was obtained by
questionnaires concerning parity, age at menarche and
cigarette smoking habits. Body weight (to the nearest 0.1 kg)
and height (to the nearest 0.01 m) were measured and the
Quetelet index (kgmg-2) was calculated as a parameter of
obesity. The oestrogen receptor (ER) content of the primary
tumour was determined as described before (Korsten, 1977),
and was known for 22 matched pairs.
The BMD of the lumbar spine was determined by dual
photon absorptiometry as described by Riggs et al. (1982)
using a Lunar DP3 scanner (Lunar Radiation Corp.,
Madison, WI, USA) with a 1 Ci "'Gd source (Amersham
Int., UK) with photopeaks at 44 and 100 keV. The precision
of the method was 2.3%. All determinations were done by
one observer within a 3-month period. The mean of BMD
values determined over L2-4 was calculated.
Analysis of variance was used to determine any significant
(P<0.05) differences among the two groups of patients. Data
showing a skewed distribution were also analysed after log
transformation.
Results
Thirty-one of the 44 (71%) cases treated with adjuvant
chemotherapy were post-menopausal at the time of the inves-
tigation compared to only seven of the 44 (16%) controls.
Most of the post-menopausal cases had their last menstrual
period during chemotherapy, all of them recalling that
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amenorrhoea began within one year from the start of
chemotherapy. Menopause in the cases occurred at a mean
age of 41 years compared to the normal menopausal age of
51-52 in Dutch women (De Waard, 1981). The seven cont-
rols became amenorrhoeic at a mean age of 47 years.
Table I shows the results of BMD determinations. The
mean BMD values are given for the case-control pairs
matched for age and year of breast cancer surgery and
grouped according to menopausal status at the time of BMD
measurement. BMD values did not differ between cases and
controls if both were either premenopausal or post-
menopausal at the time of the measurement. The important
finding was the significant difference in BMD between post-
menopausal cases and premenopausal matched controls, the
former showing approximately 10% lower mean values com-
pared to the latter. The difference in BMD between the two
pairs of still premenopausal cases and post-menopausal cont-
rols was also significant, again demonstrating a higher BMD
in premenopausal women. Post-menopausal cases had a
significantly lower BMD than premenopausal cases. When
controlled for Quetelet index, BMD was significantly related
to menopausal status in both cases and controls. Analysis of
variance demonstrated that the effect of menopausal status
on BMD was comparable in cases and controls. No BMD
differences were found when menopausal status and Quetelet
index were controlled for. The age at menopause, parity or
the amount of cigarettes smoked daily had no significant
influence. Differences in obesity were not related to BMD
differences within pairs. Both in the case and in the control
groups BMD was positively correlated with obesity
(P = 0.013), controlled for menopausal status (Figure 1). The
relationship between BMD and age is demonstrated in
Figure 2. Although age is known to be inversely related to
BMD, the large variation in BMD between our patients
obscures this correlation. The ER content of the primary
tumour which was known for 22 pairs, had no relation with
BMD.
Discussion
We have confirmed earlier reports (Bonadonna et al., 1985)
that the majority of premenopausal women lost ovarian func-
tion as a direct result of six cycles of adjuvant CMF
chemotherapy after breast cancer surgery. Our data also
show the negative relationship of menopause and BMD as
determined over the lumbar spine. It is known that the
cessation of ovarian function mainly affects trabecular bone,
which constitutes a large part of the vertebral bodies (Riggs
et al., 1981, 1982, 1986; Genant et al., 1982; Johnston et al.,
1985; Richelson et al., 1984). In this study BMD differences
between the paired cases and controls, matched for
chronological age and age at breast surgery, were only
explainable by menopausal status. Although we could
confirm the positive relationship between obesity and various
parameters of bone mass reported by others (Frumar et al.,
1980; Daniell, 1976; Kreiger et al., 1982), and Quetelet index
did not significantly contribute to the observed BMD
differences between cases and controls. Since oestrogens are
generally considered to protect women from physiological
bone loss, we have investigated whether factors, other than
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Figure 1 Lumbar bone mineral density and Quet6let index in 37
premenopausal (- *) and 51 post-menopausal (0-0)
women curatively treated for breast cancer (mean ± s.d.).
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Figure 2 Lumbar bone mineral density and age in 37 pre-
menopausal (0 0) and 51 post-menopausal (0-0) women
curatively treated for breast cancer (mean ± s.d.)
menopause, which influence the exposure of the skeleton to
oestrogens were related to BMD. However, coitrary to what
might be expected, parity and (early) age at menarche were
not (positively) related to bone mass. Smoking may enhance
both the metabolic inactivation of oestrogens (Jensen et al.,
1985) and early menopause (Lesko et al., 1985), and
therefore could have a negative influence on BMD. Our data
do not support this hypothesis. ER-positive breast cancers
may be considered to have undergone a selective growth
advantage from a milieu which is relatively rich in oest-
rogens. However, BMD and ER content of the primary
tumour in our patients were not related.
The purpose of our study was to investigate whether
adjuvant chemotherapy may precipitate accelerated post-
menopausal loss of bone mineral density. Only prospective
studies can demonstrate whether a certain reduction of BMD
will lead to an increased risk of osteoporotic fractures. How-
ever, recent reports have shown that BMD as measured in
Table I Comparison ofmean lumbar bone mineral density (BMD) between pairs ofcases and controls, matched for age and year ofbreast
surgery and grouped according to menopausal status
Cases Premenopausal Post-menopausal Post-menopausal Post-menopausal
Controls Premenopausal Post-menopausal Premenopausal Post-menopausal
(n= 11) (n = 2) (n = 26) (n =5)
BMD cases (gcm 2) 1.336 1.473 1.168 1.087
BMD controls (gcm 2) 1.349 1.206 1.285 1.335
Difference (g cm-2) -0.013 +0.267 -0.118 -0.248
s.e. difference 0.061 0.063 0.037 0.081
pa n.s. 0.036 0.036 n.s.
aAnalysis of variance.
a . .- I
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the present study is significantly reduced in osteoporotic
women compared to controls (Riggs et al., 1981; Kr0lner &
Nielsen, 1982). Our findings strongly suggest that the
accelerated bone loss resulting from premature menopause
may eventually contribute to an increased risk of
osteoporosis at a relative early age. Seventy-one per cent of
the women receiving chemotherapy lost their ovarian protec-
tion at a mean age of 41, which in The Netherlands is some
10 years early (De Waard, 1981). The limitations of the study
size and its cross-sectional model do not allow further con-
clusions. The risk of osteoporotic fractures of the spine, hip
and wrist is already considerable in the general female
population aged 60-70 (Riggs et al., 1986). If BMD is a
good predictor our findings strongly suggest that a similar
risk may apply to breast cancer patients reaching the age of
50-60 who were premenopausal when receiving adjuvant
CMF chemotherapy. The high incidence of breast cancer in
the Western industrialised world and the widely recom-
mended use of adjuvant chemotherapy in premenopausal
breast cancer (Consensus Development Conference Report,
1985; Bonadonna & Valagussa, 1987) constitute an extra
challenge to develop effective measures other than exogenous
oestrogens to reduce post-menopausal bone loss.
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